HANSOH PHARMAC Cash And Equivalents vs. Total Debt
| 3KY Stock | EUR 2.16 0.06 2.70% |
For HANSOH PHARMAC profitability analysis, we use financial ratios and fundamental drivers that measure the ability of HANSOH PHARMAC to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well HANSOH PHARMAC HD 00001 utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between HANSOH PHARMAC's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of HANSOH PHARMAC HD 00001 over time as well as its relative position and ranking within its peers.
HANSOH |
HANSOH PHARMAC HD Total Debt vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining HANSOH PHARMAC's current stock value. Our valuation model uses many indicators to compare HANSOH PHARMAC value to that of its competitors to determine the firm's financial worth. HANSOH PHARMAC HD 00001 is rated fifth in cash and equivalents category among its peers. It is rated below average in total debt category among its peers making up about 0.01 of Total Debt per Cash And Equivalents. The ratio of Cash And Equivalents to Total Debt for HANSOH PHARMAC HD 00001 is roughly 148.03 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the HANSOH PHARMAC's earnings, one of the primary drivers of an investment's value.HANSOH Total Debt vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
HANSOH PHARMAC |
| = | 13.73 B |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
HANSOH PHARMAC |
| = | 92.75 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
HANSOH Total Debt vs Competition
HANSOH PHARMAC HD 00001 is rated below average in total debt category among its peers. Total debt of Drug Manufacturers—Specialty & Generic industry is presently estimated at about 4.22 Trillion. HANSOH PHARMAC adds roughly 92.75 Million in total debt claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
HANSOH PHARMAC Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in HANSOH PHARMAC, profitability is also one of the essential criteria for including it into their portfolios because, without profit, HANSOH PHARMAC will eventually generate negative long term returns. The profitability progress is the general direction of HANSOH PHARMAC's change in net profit over the period of time. It can combine multiple indicators of HANSOH PHARMAC, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals and active pharmaceutical ingredients in the Peoples Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd. HANSOH PHARMAC operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 11645 people.
HANSOH Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on HANSOH PHARMAC. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of HANSOH PHARMAC position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the HANSOH PHARMAC's important profitability drivers and their relationship over time.
Use HANSOH PHARMAC in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HANSOH PHARMAC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HANSOH PHARMAC will appreciate offsetting losses from the drop in the long position's value.HANSOH PHARMAC Pair Trading
HANSOH PHARMAC HD 00001 Pair Trading Analysis
The ability to find closely correlated positions to HANSOH PHARMAC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HANSOH PHARMAC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HANSOH PHARMAC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HANSOH PHARMAC HD 00001 to buy it.
The correlation of HANSOH PHARMAC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HANSOH PHARMAC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HANSOH PHARMAC HD moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HANSOH PHARMAC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your HANSOH PHARMAC position
In addition to having HANSOH PHARMAC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Industrials ETFs Thematic Idea Now
Industrials ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Industrials ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Industrials ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in HANSOH Stock
To fully project HANSOH PHARMAC's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of HANSOH PHARMAC HD at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include HANSOH PHARMAC's income statement, its balance sheet, and the statement of cash flows.